NPCE

Neuropace Inc. (NPCE) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2026. Neuropace Inc. is a medical device company focused on the RNS System, a brain-responsive neuromodulation system for treating drug-resistant focal epilepsy. The company is classified as an emerging growth company and a smaller reporting company. A significant strategic shift occurred during the period with the abandonment of its DIXI Medical product operations, which are now presented as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 17% year-over-year for the quarter and 19% for the six-month period, driven by higher volumes of RNS System initial implants and replacements.
• Discontinued Operations: The DIXI Medical distribution agreement expired in September 2025, and operations were fully wound down by December 31, 2025. Consequently, there was no revenue or income from discontinued operations in the current period, compared to $1.4 million of net income from discontinued operations in the prior year quarter.
• Debt Restructuring: The company repaid its previous CRG Term Loan in June 2025 and replaced it with a $60.0 million MidCap Term Loan. This resulted in lower interest expense in the current period compared to the prior year.
• Expense Management: General and administrative expenses decreased 17% for the quarter, primarily due to the absence of one-time severance and transition costs recorded in the prior year.

Guidance, Outlook, and Risks

• Regulatory Status: The FDA notified the company in July 2026 that its Premarket Approval Supplement (PMA-S) for expanding indications to patients with drug-resistant idiopathic generalized epilepsy (IGE) is not approvable in its current form. The company plans to submit a Submission Issue Request and amend the PMA-S with additional data.
• Liquidity: Management believes current cash, cash equivalents, and short-term investments ($51.7 million) are sufficient to fund operations for at least the next 12 months. The company is currently in compliance with all financial covenants of the MidCap Credit Agreement, including minimum liquidity thresholds.
• Strategic Focus: The company is expanding commercial efforts to target epileptologists and neurosurgeons outside of Level 4 Comprehensive Epilepsy Centers (CECs) and is investing in clinical studies for pediatric indications (ages 12-17).
• Risks: Key risks include the inability to achieve profitability, dependence on single-source suppliers, potential delays in regulatory approvals for label expansion, and the impact of the expiration of the DIXI Medical agreement on long-term revenue growth projections.

Investor Verification Checklist

• Regulatory Pathway: Verify the timeline and requirements for the amended PMA-S submission regarding the IGE indication expansion following the FDA's July 2026 correspondence.
• Debt Covenants: Monitor compliance with the MidCap Credit Agreement's minimum liquidity covenants ($60.0 million threshold until June 2027) and trailing 12-month revenue requirements.
• Discontinued Operations: Confirm that all DIXI Medical inventory has been returned and no residual liabilities remain from the wind-down of that business line.
• Cash Burn Rate: Assess the sustainability of the current operating cash burn (~$10 million per six months) against the $51.7 million cash balance to validate the 12-month runway assertion.
• Supply Chain: Review the status of single-source suppliers for critical components (e.g., batteries, printed circuit assemblies) and any contingency plans for supply disruptions.